Innovation In Ophthalmology Corporate Overview March 2021 NOT FOR PROMOTIONAL USE Disclaimers and Notices This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding Company's products, EYSUVISTM, for the short term (up to two weeks) relief of the signs and symptoms of dry eye disease, INVELTYS®, the first and only topical twice-daily ocular corticosteroid fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or other ju ...

Start Time: 08:00 January 1, 0000 8:48 AM ET Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q4 2020 Earnings Conference Call February 25, 2021, 08:00 AM ET Company Participants Mark Iwicki - Chairman, President and CEO Mary Reumuth - CFO Todd Bazemore - COO Kim Brazzell - Chief Medical Officer Hongming Chen - Chief Scientific Officer Niranjan Kameswaran - SVP, Strategy Conference Call Participants Christopher Neyor - JPMorgan Andreas Argyrides - Wedbush Securities François Brisebois - Oppenheimer Biren Amin - Jef ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q3 2020 Earnings Conference Call November 5, 2020 8:00 AM ET Company Participants Niranjan Kameswaran - SVP, Strategy Mary Reumuth - CFO Mark Iwicki - Chairman, President and CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Office Conference Call Participants Liana Moussatos - Wedbush Securities Christopher Neyor - JPMorgan François Brisebois - Oppenheimer Yi Chen - H.C. Wainwright Operator Good morning, and welcome to the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q2 2020 Earnings Conference Call August 6, 2020 8:00 AM ET Company Participants Niranjan Kameswaran - SVP, Strategy Mary Reumuth - CFO Mark Iwicki - Chairman, President and CEO Kim Brazzell - Chief Medical Officer Todd Bazemore - COO Hongming Chen - Chief Scientific Officer Conference Call Participants Christopher Neyor - JPMorgan Kit Ma - Jefferies Yi Chen - H.C. Wainwright François Brisebois - Oppenheimer Tazeen Ahmad - Bank of America Andreas Argyrides - Wedbush S ...

Innovation In Ophthalmics Corporate Overview August 2020 NOT FOR PROMOTIONAL USE 2 Disclaimers and Notices This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties, including statements regarding INVELTYS® and its commercial progress, the Company's lead product candidate, EYSUVISTM, for the short-term relief of the signs and symptoms of dry eye disease, including expectations regarding t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or othe ...

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Q1 2020 Earnings Conference Call May 7, 2020 8:00 AM ET Company Participants Niranjan Kameswaran - Senior Vice President, Strategy Mary Reumuth - Chief Financial Officer Mark Iwicki - Chairman, President and Chief Executive Officer Kim Brazzell - Chief Medical Officer Todd Bazemore - Chief Operating Officer Conference Call Participants Chris Neyor - JP Morgan Liana Moussatos - Wedbush Securities Biren Amin - Jefferies LLC Yi Chen - H.C. Wainwright & Co. Tazeen Ahmad ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38150 KALA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 27-0604595 (State or oth ...